Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2001 May;158(5):1561-3.
doi: 10.1016/S0002-9440(10)64109-0.

Loss of heterozygosity or intragenic mutation, which comes first?

R E Wilentz  1 , P Argani, R H Hruban
Affiliations
Comment

Loss of heterozygosity or intragenic mutation, which comes first?

R E Wilentz et al. Am J Pathol. 2001 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Inactivation of tumor-suppressor genes. Inactivation of a tumor-suppressor gene requires inactivation of both of its alleles. This commonly occurs by intragenic mutation (IM) in one allele coupled with loss of the other allele (LOH). This diagram presents three different scenarios for the timing of these events. The circle represents a previously characterized gene allele. The square represents a yet undiscovered gene allele. An X represents an IM in one of these two genes. A: IM occurs before LOH of a single gene. B: LOH is the first hit. C: IM occurs in a yet undiscovered gene (square) that is located on the same chromosomal arm as a previously characterized gene under study. LOH then takes place on this chromosomal arm. Lastly, the gene under study (circle) becomes mutated, and it too is biallelically inactivated. (Artwork by Jennifer L. Parsons, M. A.)
See this image and copyright information in PMC

Comment on

References

    1. Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, Hahn SA: Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001, 158:1677-1683 - PMC - PubMed
    1. Heinmöller E, Dietmaier W, Zirngibl H, Heinmöller P, Scaringe W, Jauch K-W, Hofstädter F, Rüschoff J: Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 2000, 157:83-92 - PMC - PubMed
    1. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T: Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000, 156:2123-2133 - PMC - PubMed
    1. Wilentz RE, Geradts J, Maynard R, Offerhaus GJA, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH: Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998, 58:4740-4744 - PubMed
    1. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-2006 - PubMed

Publication types

MeSH terms

LinkOut - more resources